ReviewCell reports2024
Bacteriophages, gut bacteria, and microbial pathways interplay in cardiometabolic health.
Review in Cell reports, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 21 citations in OpenAlex.
- Article
- Post-Microbial Therapeutics for the Next Generation of Medicine.MicrobiologyOpen · 2026Review
- Remodelling of the gut virome after long-term fasting.NPJ biofilms and microbiomes · 2026Article
- Microbiome modulating remedies for chronic diseases: a review of current interventions and future directions.Inflammopharmacology · 2026Review
- Unveiling the viral dimension: The paediatric gut virome as a key modulator of gastrointestinal metabolic, and neurodevelopmental health.World journal of virology · 2026Review
- Review
- Gut phages are linked to off-target antimicrobial resistance genes in orthopedic patients receiving peri-surgical antibiotics.Frontiers in microbiology · 2026Article
- Associations and interactions between prokaryotes and other gut biota in non-human primates.Primates; journal of primatology · 2026Review
- Fecal microbiota transplantation in adolescents with obesity induces limited and donor-dependent remodeling of the gut microbiome.Frontiers in endocrinology · 2026Article
- Beyond bacterial dysbiosis: the emerging role of gut bacteriophages in type 2 diabetes.Frontiers in cell and developmental biology · 2026Review
- Exploring diversity and distribution patterns of chicken gut bacteriophage community.Animal microbiome · 2025Article
- A bacterial and viral genome catalogue from Atlantic salmon highlights diverse gut microbiome compositions at pre- and post-smolt life stages.Animal microbiome · 2025Article
- The respiratory tract virome: unravelling the role of viral dark matter in respiratory health and disease.European respiratory review : an official journal of the European Respiratory Society · 2025Review
- Article
- Human Gut Bacteriophageome: Insights Into Drug Resistance Mechanisms in Tuberculosis.Interdisciplinary perspectives on infectious diseases · 2025Review
- Evaluating phage lytic activity: from plaque assays to single-cell technologies.Frontiers in microbiology · 2025Review
- Phage therapy could be key to conquering persistent bacterial lung infections in children.npj antimicrobials and resistance · 2024Review
- Does Phage Therapy Need a Pan-Phage?Pathogens (Basel, Switzerland) · 2024Review
- Human and gut microbiota synergy in a metabolically active superorganism: a cardiovascular perspective.Frontiers in cardiovascular medicine · 2024Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 3 institutions in 4 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Cardiometabolic diseases are leading causes of mortality in Western countries. Well-established risk factors include host genetics, lifestyle, diet, and the gut microbiome. Moreover, gut bacterial communities and their activities can be altered by bacteriophages (also known simply as phages), bacteria-infecting viruses, making these biological entities key regulators of human cardiometabolic health. The manipulation of bacterial populations by phages enables the possibility of using phages in the treatment of cardiometabolic diseases through phage therapy and fecal viral transplants. First, however, a deeper understanding of the role of the phageome in cardiometabolic diseases is required. In this review, we first introduce the phageome as a component of the gut microbiome and discuss fecal viral transplants and phage therapy in relation to cardiometabolic diseases. We then summarize the current state of phageome research in cardiometabolic diseases and propose how the phageome might indirectly influence cardiometabolic health through gut bacteria and their metabolites.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.